{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T15:57:50Z","timestamp":1791734270154,"version":"4.3.4"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T00:00:00Z","timestamp":1522713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1038\/s41416-018-0035-8","type":"journal-article","created":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T22:51:46Z","timestamp":1522363906000},"page":"1217-1228","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":74,"title":["Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: a prospective observational cohort study"],"prefix":"10.1038","volume":"118","author":[{"given":"Julia","family":"Bergheim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Semaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidrun","family":"Gevensleben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Groening","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Knoblich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rn","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg C.","family":"Kalff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"Bootz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen","family":"Kristiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9794-7927","authenticated-orcid":false,"given":"Dimo","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,3]]},"reference":[{"key":"35_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2017. CA Cancer J. Clin. 67, 7\u201330 (2017).","journal-title":"CA Cancer J. Clin."},{"key":"35_CR2","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1016\/S0140-6736(13)61649-9","volume":"383","author":"H Brenner","year":"2014","unstructured":"Brenner, H., Kloor, M. & Pox, C. P. Colorectal cancer. Lancet 383, 1490\u20131502 (2014).","journal-title":"Lancet"},{"key":"35_CR3","unstructured":"Amin M. B., et al. (eds). AJCC Cancer Staging Manual 8th edn (Springer International Publishing: Basel, Switzerland, 2016)."},{"key":"35_CR4","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1002\/cncr.30181","volume":"122","author":"L Casadaban","year":"2016","unstructured":"Casadaban, L. et al. Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer. Cancer 122, 3277\u20133287 (2016).","journal-title":"Cancer"},{"key":"35_CR5","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.jamcollsurg.2014.09.010","volume":"219","author":"SH Fang","year":"2014","unstructured":"Fang, S. H., Efron, J. E., Berho, M. E. & Wexner, S. D. Dilemma of stage II colon cancer and decision making for adjuvant chemotherapy. J. Am. Coll. Surg. 219, 1056\u20131069 (2014).","journal-title":"J. Am. Coll. Surg."},{"key":"35_CR6","doi-asserted-by":"publisher","first-page":"157","DOI":"10.4329\/wjr.v7.i7.157","volume":"7","author":"PP Mainenti","year":"2015","unstructured":"Mainenti, P. P. et al. Non-invasive diagnostic imaging of colorectal liver metastases. World J. Radiol. 7, 157\u2013169 (2015).","journal-title":"World J. Radiol."},{"key":"35_CR7","doi-asserted-by":"crossref","unstructured":"Niekel, M. C, Bipat, S. & Stoker, J. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and\/or FDG PET\/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology 257, 674\u2013684 (2010).","DOI":"10.1148\/radiol.10100729"},{"key":"35_CR8","doi-asserted-by":"publisher","first-page":"20150836","DOI":"10.1259\/bjr.20150836","volume":"90","author":"B Barbaro","year":"2017","unstructured":"Barbaro, B. et al. The potential predictive value of MRI and PET-CT in mucinous and nonmucinous rectal cancer to identify patients at high risk of metastatic disease. Br. J. Radiol. 90, 20150836 (2017).","journal-title":"Br. J. Radiol."},{"key":"35_CR9","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.6004\/jnccn.2014.0099","volume":"12","author":"AB Benson 3rd","year":"2014","unstructured":"Benson, A. B. 3rd, National Comprehensive Cancer Network. et al. Colon cancer, version 3.2014. J. Natl Compr. Canc Netw. 12, 1028\u20131059 (2014).","journal-title":"J. Natl Compr. Canc Netw."},{"key":"35_CR10","doi-asserted-by":"publisher","first-page":"e231","DOI":"10.1097\/MD.0000000000000231","volume":"93","author":"L Huang","year":"2014","unstructured":"Huang, L. et al. Neoadjuvant chemotherapy followed by surgery versus surgery alone for colorectal cancer: meta-analysis of randomized controlled trials. Medicine 93, e231 (2014).","journal-title":"Medicine"},{"key":"35_CR11","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nrclinonc.2013.110","volume":"10","author":"E Crowley","year":"2013","unstructured":"Crowley, E., Di Nicolantonio, F., Loupakis, F. & Bardelli, A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat. Rev. Clin. Oncol. 10, 472\u2013484 (2013).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"35_CR12","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1373\/clinchem.2014.222679","volume":"61","author":"E Heitzer","year":"2015","unstructured":"Heitzer, E., Ulz, P. & Geigl, J. B. Circulating tumour DNA as a liquid biopsy for cancer. Clin. Chem. 61, 112\u2013123 (2015).","journal-title":"Clin. Chem."},{"key":"35_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-016-0299-x","volume":"8","author":"V Branchi","year":"2016","unstructured":"Branchi, V. et al. Promoter hypermethylation of SHOX2 and SEPT9 is a potential biomarker for minimally invasive diagnosis in adenocarcinomas of the biliary tract. Clin. Epigenetics 8, 133 (2016).","journal-title":"Clin. Epigenetics"},{"key":"35_CR14","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1136\/gutjnl-2012-304149","volume":"63","author":"TR Church","year":"2014","unstructured":"Church, T. R., PRESEPT Clinical Study Steering Committee, Investigators and Study Team. et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut 63, 317\u2013325 (2014).","journal-title":"Gut"},{"key":"35_CR15","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1373\/clinchem.2016.270207","volume":"63","author":"A Schr\u00f6ck","year":"2017","unstructured":"Schr\u00f6ck, A. et al. Free-circulating methylated DNA in blood for diagnosis, staging, prognosis, and monitoring of head and neck squamous cell carcinoma patients: an observational prospective cohort study. Clin. Chem. 63, 1288\u20131296 (2017).","journal-title":"Clin. Chem."},{"key":"35_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-016-0267-5","volume":"8","author":"A Semaan","year":"2016","unstructured":"Semaan, A. et al. SEPT9 and SHOX2 DNA methylation status and its utility in the diagnosis of colonic adenomas and colorectal adenocarcinomas. Clin. Epigenetics 8, 100 (2016).","journal-title":"Clin. Epigenetics"},{"key":"35_CR17","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3233\/CBM-160321","volume":"18","author":"L Song","year":"2017","unstructured":"Song, L., Yu, H., Jia, J. & Li, Y. A systematic review of the performance of the SEPT9 gene methylation assay in colorectal cancer screening, monitoring, diagnosis and prognosis. Cancer Biomark. 18, 425\u2013432 (2017).","journal-title":"Cancer Biomark."},{"key":"35_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-398","volume":"13","author":"R Wasserkort","year":"2013","unstructured":"Wasserkort, R. et al. Aberrant septin 9 DNA methylation in colorectal cancer is restricted to a single CpG island. BMC Cancer 13, 398 (2013).","journal-title":"BMC Cancer"},{"key":"35_CR19","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1097\/JTO.0b013e318220ef9a","volume":"6","author":"C Kneip","year":"2011","unstructured":"Kneip, C. et al. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer in plasma. J. Thorac. Oncol. 6, 1632\u20131638 (2011).","journal-title":"J. Thorac. Oncol."},{"key":"35_CR20","doi-asserted-by":"publisher","first-page":"e0118195","DOI":"10.1371\/journal.pone.0118195","volume":"10","author":"B Schmidt","year":"2015","unstructured":"Schmidt, B. et al. Quantification of cell-free mSHOX2 Plasma DNA for therapy monitoring in advanced stage non-small cell (NSCLC) and small-cell lung cancer (SCLC) patients. PLoS ONE 10, e0118195 (2015).","journal-title":"PLoS ONE"},{"key":"35_CR21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jtho.2016.08.123","volume":"12","author":"G Weiss","year":"2017","unstructured":"Weiss, G., Schlegel, A., Kottwitz, D., K\u00f6nig, T. & Tetzner, R. Validation of the SHOX2\/PTGER4 DNA methylation marker panel for plasma-based discrimination between patients with malignant and nonmalignant lung disease. J. Thorac. Oncol. 12, 77\u201384 (2017).","journal-title":"J. Thorac. Oncol."},{"key":"35_CR22","doi-asserted-by":"publisher","first-page":"e84225","DOI":"10.1371\/journal.pone.0084225","volume":"8","author":"D Dietrich","year":"2013","unstructured":"Dietrich, D. et al. Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant and malignant pleural effusions. PLoS ONE 8, e84225 (2013).","journal-title":"PLoS ONE"},{"key":"35_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-016-0192-7","volume":"8","author":"M Jung","year":"2016","unstructured":"Jung, M. et al. Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant, and malignant ascites. Clin. Epigenetics 8, 24 (2016).","journal-title":"Clin. Epigenetics"},{"key":"35_CR24","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/978-3-319-42044-8_32","volume":"924","author":"J Distler","year":"2016","unstructured":"Distler, J. et al. Evaluation of different blood collection tubes and blood storage conditions for the preservation and stability of cell-free circulating DNA for the analysis of the methylated (m)SEPT9 colorectal cancer screening marker. Adv. Exp. Med. Biol. 924, 175\u2013178 (2016).","journal-title":"Adv. Exp. Med. Biol."},{"key":"35_CR25","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/(SICI)1097-0142(20000401)88:7<1739::AID-CNCR30>3.0.CO;2-T","volume":"88","author":"C Compton","year":"2000","unstructured":"Compton, C., Fenoglio-Preiser, C. M., Pettigrew, N. & Fielding, L. P. American joint committee on cancer prognostic factors consensus conference: colorectal working group. Cancer 88, 1739\u20131757 (2000).","journal-title":"Cancer"},{"key":"35_CR26","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1001\/jamasurg.2015.0871","volume":"150","author":"P Thirunavukarasu","year":"2015","unstructured":"Thirunavukarasu, P. et al. Effect of incorporation of pretreatment serum carcinoembryonic antigen levels into AJCC staging for colon cancer on 5-year survival. JAMA Surg. 150, 747\u2013755 (2015).","journal-title":"JAMA Surg."},{"key":"35_CR27","first-page":"400","volume":"58","author":"M Basbug","year":"2011","unstructured":"Basbug, M. et al. Prognostic value of preoperative CEA and CA 19-9 levels in patients with colorectal cancer. Hepatogastroenterology 58, 400\u2013405 (2011).","journal-title":"Hepatogastroenterology"},{"key":"35_CR28","doi-asserted-by":"crossref","first-page":"837","DOI":"10.5858\/134.6.837","volume":"134","author":"G Puppa","year":"2010","unstructured":"Puppa, G., Sonzogni, A., Colombari, R. & Pelosi, G. TNM staging system of colorectal carcinoma: a critical appraisal of challenging issues. Arch. Pathol. Lab Med. 134, 837\u2013852 (2010).","journal-title":"Arch. Pathol. Lab Med."},{"key":"35_CR29","doi-asserted-by":"publisher","first-page":"116","DOI":"10.4240\/wjgs.v7.i7.116","volume":"7","author":"AH Choi","year":"2015","unstructured":"Choi, A. H. et al. Accuracy of computed tomography in nodal staging of colon cancer patients. World J. Gastrointest. Surg. 7, 116\u2013122 (2015).","journal-title":"World J. Gastrointest. Surg."},{"key":"35_CR30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/codi.13091","volume":"18","author":"A Sj\u00f6vall","year":"2016","unstructured":"Sj\u00f6vall, A., Blomqvist, L., Egenvall, M., Johansson, H. & Martling, A. Accuracy of preoperative T and N staging in colon cancer\u2212a national population-based study. Colorectal Dis. 18, 73\u201379 (2016).","journal-title":"Colorectal Dis."},{"key":"35_CR31","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S1470-2045(17)30438-2","volume":"18","author":"B O\u2019Sullivan","year":"2017","unstructured":"O\u2019Sullivan, B. et al. The TNM classification of malignant tumours-towards common understanding and reasonable expectations. Lancet Oncol. 18, 849\u2013851 (2017).","journal-title":"Lancet Oncol."},{"key":"35_CR32","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s00432-017-2363-0","volume":"143","author":"L Song","year":"2017","unstructured":"Song, L. et al. The performance of the mSEPT9 assay is influenced by algorithm, cancer stage and age, but not sex and cancer location. J. Cancer Res. Clin. Oncol. 143, 1093\u20131101 (2017).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"35_CR33","doi-asserted-by":"publisher","first-page":"e46000","DOI":"10.1371\/journal.pone.0046000","volume":"7","author":"K T\u00f3th","year":"2012","unstructured":"T\u00f3th, K. et al. Detection of methylated SEPT9 in plasma is a reliable screening method for both left- and right-sided colon cancers. PLoS ONE 7, e46000 (2012).","journal-title":"PLoS ONE"},{"key":"35_CR34","doi-asserted-by":"publisher","first-page":"e115415","DOI":"10.1371\/journal.pone.0115415","volume":"9","author":"K T\u00f3th","year":"2014","unstructured":"T\u00f3th, K. et al. Detection of methylated septin 9 in tissue and plasma of colorectal patients with neoplasia and the relationship to the amount of circulating cell-free DNA. PLoS ONE 9, e115415 (2014).","journal-title":"PLoS ONE"},{"issue":"15_suppl","key":"35_CR35","doi-asserted-by":"publisher","first-page":"e15160","DOI":"10.1200\/JCO.2017.35.15_suppl.e15160","volume":"35","author":"NPM Brouwer","year":"2017","unstructured":"Brouwer, N. P. M. et al. Clinical lymph node staging by imaging in colorectal cancer: a flip of the coin? J. Clin. Oncol. 35(15_suppl), e15160 (2017).","journal-title":"J. Clin. Oncol."},{"key":"35_CR36","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.suronc.2016.12.006","volume":"26","author":"M Samim","year":"2017","unstructured":"Samim, M. et al. The diagnostic performance of (18)F-FDG PET\/CT, CT and MRI in the treatment evaluation of ablation therapy for colorectal liver metastases: a systematic review and meta-analysis. Surg. Oncol. 26, 37\u201345 (2017).","journal-title":"Surg. Oncol."},{"key":"35_CR37","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1136\/gutjnl-2014-308859","volume":"65","author":"T Reinert","year":"2016","unstructured":"Reinert, T. et al. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut 65, 625\u2013634 (2016).","journal-title":"Gut"},{"key":"35_CR38","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1245\/s10434-016-5717-y","volume":"24","author":"A Acharya","year":"2017","unstructured":"Acharya, A., Markar, S. R., Matar, M., Ni, M. & Hanna, G. B. Use of tumour markers in gastrointestinal cancers: surgeon perceptions and cost-benefit trade-off analysis. Ann. Surg. Oncol. 24, 1165\u20131173 (2017).","journal-title":"Ann. Surg. Oncol."},{"key":"35_CR39","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00384-017-2772-1","volume":"32","author":"H Ozawa","year":"2017","unstructured":"Ozawa, H. et al. Incorporation of serum carcinoembryonic antigen levels into the prognostic grouping system of colon cancer. Int J. Colorectal Dis. 32, 821\u2013829 (2017).","journal-title":"Int J. Colorectal Dis."},{"key":"35_CR40","doi-asserted-by":"publisher","first-page":"907","DOI":"10.17219\/acem\/37334","volume":"23","author":"A Esteghamati","year":"2014","unstructured":"Esteghamati, A. et al. The role of metabolic syndrome and related clinical variables in determining CEA levels. Adv. Clin. Exp. Med 23, 907\u2013912 (2014).","journal-title":"Adv. Clin. Exp. Med"},{"key":"35_CR41","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3393\/ac.2013.29.3.106","volume":"29","author":"BG Jeon","year":"2013","unstructured":"Jeon, B. G., Shin, R., Chung, J. K., Jung, I. M. & Heo, S. C. Individualized cutoff value of the preoperative carcinoembryonic antigen level is necessary for optimal use as a prognostic marker. Ann. Coloproctol. 29, 106\u2013114 (2013).","journal-title":"Ann. Coloproctol."},{"key":"35_CR42","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.1245\/s10434-008-0168-8","volume":"15","author":"R Takagawa","year":"2008","unstructured":"Takagawa, R. et al. Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer. Ann. Surg. Oncol. 15, 3433\u20133439 (2008).","journal-title":"Ann. Surg. Oncol."},{"key":"35_CR43","first-page":"105","volume":"3","author":"UK Ballehaninna","year":"2012","unstructured":"Ballehaninna, U. K. & Chamberlain, R. S. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal. J. Gastrointest. Oncol. 3, 105\u2013119 (2012).","journal-title":"J. Gastrointest. Oncol."},{"key":"35_CR44","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/1471-230X-14-183","volume":"14","author":"A Adler","year":"2014","unstructured":"Adler, A. et al. Improving compliance to colorectal cancer screening using blood and stool based tests in patients refusing screening colonoscopy in Germany. BMC Gastroenterol. 14, 183 (2014).","journal-title":"BMC Gastroenterol."},{"key":"35_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-03321-8","volume":"7","author":"L Song","year":"2017","unstructured":"Song, L., Jia, J., Peng, X., Xiao, W. & Li, Y. The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests: a meta-analysis. Sci. Rep. 7, 3032 (2017).","journal-title":"Sci. Rep."},{"key":"35_CR46","doi-asserted-by":"publisher","first-page":"5416","DOI":"10.1158\/1078-0432.CCR-16-3155","volume":"23","author":"F Garlan","year":"2017","unstructured":"Garlan, F. et al. Early evaluation of circulating tumour DNA as marker of therapeutic efficacy in metastatic colorectal cancer patients (PLACOL Study). Clin. Cancer Res. 23, 5416\u20135425 (2017).","journal-title":"Clin. Cancer Res."},{"key":"35_CR47","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1373\/clinchem.2015.253609","volume":"62","author":"S Garrigou","year":"2016","unstructured":"Garrigou, S. et al. A study of hypermethylated circulating tumour DNA as a universal colorectal cancer biomarker. Clin. Chem. 62, 1129\u20131139 (2016).","journal-title":"Clin. Chem."},{"key":"35_CR48","doi-asserted-by":"publisher","first-page":"e0133836","DOI":"10.1371\/journal.pone.0133836","volume":"10","author":"AacuteV Patai","year":"2015","unstructured":"Patai, \u00c1. V. et al. Comprehensive DNA methylation analysis reveals a common ten-gene methylation signature in colorectal adenomas and carcinomas. PLoS ONE 10, e0133836 (2015).","journal-title":"PLoS ONE"},{"key":"35_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1674-2","volume":"15","author":"SK Pedersen","year":"2015","unstructured":"Pedersen, S. K. et al. Evaluation of an assay for methylated BCAT1 and IKZF1 in plasma for detection of colorectal neoplasia. BMC Cancer 15, 654 (2015).","journal-title":"BMC Cancer"},{"issue":"11","key":"35_CR50","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1136\/gutjnl-2016-313372","volume":"67","author":"Ludovic Barault","year":"2017","unstructured":"Barault L., et al. Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. Gut. https:\/\/doi.org\/10.1136\/gutjnl-2016-313372 (2017).","journal-title":"Gut"},{"key":"35_CR51","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1080\/15592294.2017.1356957","volume":"12","author":"BK Bart\u00e1k","year":"2017","unstructured":"Bart\u00e1k, B. K. et al. Colorectal adenoma and cancer detection based on altered methylation pattern of SFRP1, SFRP2, SDC2, and PRIMA1 in plasma samples. Epigenetics 12, 751\u2013763 (2017).","journal-title":"Epigenetics"},{"key":"35_CR52","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3892\/br.2017.970","volume":"7","author":"M Zhang","year":"2017","unstructured":"Zhang, M., He, Y., Zhang, X., Zhang, M. & Kong, L. A pooled analysis of the diagnostic efficacy of plasmic methylated septin-9 as a novel biomarker for colorectal cancer. Biomed. Rep. 7, 353\u2013360 (2017).","journal-title":"Biomed. Rep."},{"key":"35_CR53","doi-asserted-by":"publisher","first-page":"e0180809","DOI":"10.1371\/journal.pone.0180809","volume":"12","author":"SL Rasmussen","year":"2017","unstructured":"Rasmussen, S. L. et al. Hypermethylated DNA, a circulating biomarker for colorectal cancer detection. PLoS ONE 12, e0180809 (2017).","journal-title":"PLoS ONE"},{"key":"35_CR54","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.clinbiochem.2013.06.002","volume":"46","author":"SE Norton","year":"2013","unstructured":"Norton, S. E., Lechner, J. M., Williams, T. & Fernando, M. R. A stabilizing reagent prevents cell-free DNA contamination by cellular DNA in plasma during blood sample storage and shipping as determined by digital PCR. Clin. Biochem. 46, 1561\u20131565 (2013).","journal-title":"Clin. Biochem."},{"key":"35_CR55","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s12253-016-0174-2","volume":"23","author":"K T\u00f3th","year":"2017","unstructured":"T\u00f3th, K. et al. Circadian rhythm of methylated septin 9, cell-free DNA amount and tumour markers in colorectal cancer patients. Pathol. Oncol. Res. 23, 699\u2013706 (2017).","journal-title":"Pathol. Oncol. Res."},{"key":"35_CR56","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/jcla.21603","volume":"27","author":"SE Norton","year":"2013","unstructured":"Norton, S. E., Luna, K. K., Lechner, J. M., Qin, J. & Fernando, M. R. A new blood collection device minimizes cellular DNA release during sample storage and shipping when compared to a standard device. J. Clin. Lab Anal. 27, 305\u2013311 (2013).","journal-title":"J. Clin. Lab Anal."},{"issue":"R1","key":"35_CR57","doi-asserted-by":"publisher","first-page":"R7","DOI":"10.1093\/hmg\/ddt375","volume":"22","author":"AE Teschendorff","year":"2013","unstructured":"Teschendorff, A. E., West, J. & Beck, S. Age-associated epigenetic drift: implications, and a case of epigenetic thrift? Hum. Mol. Genet 22(R1), R7\u2013R15 (2013).","journal-title":"Hum. Mol. Genet"},{"key":"35_CR58","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/nm.1789","volume":"14","author":"F Diehl","year":"2008","unstructured":"Diehl, F. et al. Circulating mutant DNA to assess tumour dynamics. Nat. Med. 14, 985\u2013990 (2008).","journal-title":"Nat. Med."},{"key":"35_CR59","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1373\/clinchem.2013.203679","volume":"59","author":"SC Yu","year":"2013","unstructured":"Yu, S. C. et al. High-resolution profiling of fetal DNA clearance from maternal plasma by massively parallel sequencing. Clin. Chem. 59, 1228\u20131237 (2013).","journal-title":"Clin. Chem."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0035-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0035-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0035-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:02:03Z","timestamp":1684616523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-018-0035-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,3]]},"references-count":59,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["35"],"URL":"https:\/\/doi.org\/10.1038\/s41416-018-0035-8","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,3]]},"assertion":[{"value":"16 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The University Hospital Bonn (Principal Investigator: Dimo Dietrich) receives research funding from Epigenomics AG, Berlin, Germany. The company aims to commercialize DNA methylation biomarkers (e.g.,SHOX2andSEPT9). Remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}